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Introduction
Traumatic brain injury (TBI) is a clinical problem 
of neurosurgery which can cause disability, death on 
children, adult, and still causing economic and social 
problem. The incidence of TBI in USA is predicted on 1.6 
million cases/year with the mortality rate is 52.000 and 
neurological disability on 70.000–90.000 cases. The 
prevalence in European continent is 708.954 cases/
year with the incidence of 235/100.000 cases, and 
mortality of 15/100.000 cases among TBI [1].
In Indonesia, TBI is caused of disability in daily 
activity. The incident rate became increased every year 
from 8.2% in 2013 to be 9.2% in 2018. The highest 
prevalence rate of TBI was on age over 15–24 years 
old (12.2%), male (11%) and rural area (9.4%). Road 
traffic accident still counted high proportion (31.4%) 
but tend to low according to the previous report in year 
2013 (42.8%). Riding a motor cycle is high caused TBI 
(72.7%) and male (80.9%), respectively [2].
Traumatic brain injury (TBI) can cause 
brain tissue injury which is classified as direct injury 
(primary injury) and extension of late injury (secondary 
injury). Primary brain injury is caused by mechanical 
force which causing injury on brain directly after 
trauma (blast, laceration, bruising, hematoma, and 
bleeding). This can be caused by local, multifocal or 
diffuse injury on neuron, axon, glia, and vessels. The 
pathology changes on computerized tomography (CT) 
scan are epidural hematoma, subdural hematoma, 
intracerebral hemorrhage, diffuse axonal injury. and 
others [3].
Brain contusion is the injury of brain after the 
primary and secondary brain injury. Contusion consists 
of two zones, the central zone, and the pericontusion 
zone. On central zone, the necrotic event is irreversible, 
rupture of blood–brain barrier (BBB) and neurological 
cell death occurred [1], [3].
The research on biochemical marker and 
neuroprotective drug is based on finding of cellular 
activity on brain contusion from the acute phase 
is grow up nowadays. Clinical trials on TBI have 
concluded that marker of neuron injury S-100β, 
neuroinflammation marker interleukin 6 (IL-6), 
and canal protein marker aquaporin-4 (AQP4) are 
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expressed acutely after brain injury. The increasing 
expression of S-100β, neuroinflammation marker 
IL-6, and canal protein AQP4 on serum positively 
correlate on BBB rupture. This marker on blood 
serum can be used as marker of pathophysiological 
cascade on BBB rupture and neuronal cell death in 
TBI. S-100β and IL-6 reported as first marker of BBB 
rupture on TBI while AQP4 as the canal protein of 
water, regulator of the BBB integrity can cause the 
vasogenic and cytotoxic edema [4], [5], [6], [7], [8], 
[9], [10], [11], [12], [13], [14], [15], [16], [17].
PROG is known as a reproductive hormone 
with cellular function of regulating progestation, as 
preparing the uterus integrity on pregnancy. The 
PROG found diffusely on human neuron and has a 
pleiotropic function, the important neurobiological 
cellular function. In TBI, all mechanism of PROG 
cellularly is the main topic of neuroscience research 
nowadays [18], [19], [20], [21].
PROG role in TBI has many advantages so 
that can be used as a neuroprotective agent. Study in 
clinical trials with animals phase I and clinical phase 
II-III brain injury stated that the effect of PROG can 
protect the neuron from cellular mechanisms. The 
pharmacokinetic of PROG and effect of adverse 
reaction is safely known. PROG given from 24 h post-
trauma can reduce brain edema. PROG can cross 
the BBB fast and reaching the plasma balance after 
1 h [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], 
[28], [29], [30], [31]. Thus, we decided to use PROG in 
treatment of severe TBI for reducing the biomarkers in 
serum.
Materials and Methods
Study design 
This is an experimental, analytical study, 
with clinical trial, double-blinded, with pre- and post-
test design. This study design to determine the 
efficacy of early intramuscular administration of 
PROG versus control group for treating patients with 
acute non-penetrating severe TBI caused by a blunt 
mechanism. This study also examines the correlation 
with or within change on both groups and the outcome 
Glasgow Outcome Scale (GOS) 3 months. This study is 
done on emergency room, intensive care unit, inpatient 
ward, outpatient ward, direct communication from 
phone, and in house visit. The duration of this study 
is until the sample is enough to start the study. This 
study is done by the researcher with the help of all of 
team – Resident of Neurosurgery, Nursery Department, 
Radiology Department, and Anesthesiology Department 
of Central Hospital Dr. Soetomo Surabaya, Indonesia. 
The trial was funded by researcher its self and no 
conflicts of interest.
Study patients
Eligible patients were adults 15–60 years old, 
who had severe TBI due to a blunt mechanism, with a 
Glasgow Coma Scale (GCS) score of 4 to 8. Patients 
were enrolled, if the study treatment could be initiated 
within 24 h after injury.
Patients were excluded if, before enrollment, 
the treatment team determined clinically that the injury 
sustained was non survivable (GCS 3) and the patient 
had bilateral dilated, unresponsive pupils; penetrating 
brain injury, or the patient had physiological findings 
of hypoxemia (SaO2 <80%, PO2 <80%), hypotension 
(Systolic <90 mmHg), spinal cord injury (multitrauma), 
or early post-traumatic epilepsy. Additional 
exclusion criteria are post-traumatic hyperglycemia 
(BS >200 mg/dl) and brain CT scan showed Marshall 
type IV, evacuated mass and non-evacuated mass.
Patient were drop out if patients had 
complicated after blood test, hyperthermia (t >40°C) 
before intervention, allergy to progesterone, death 
before day 5, rejection the informed research, patient 
cannot trace the true address or family communication 
lately and need operative surgery during follow-up.
Study of biomarkers
Immediately after enrollment, patients were 
randomly assigned to examine serum level of S-100β, 
AQP4, and IL-6 on both groups. All of biomarker 
was examine in 24 h (day 1) and 96 h (day 4). In 
treated group, the serum was talked before gave 
the intervention. All of biomarker was processed by 
ELISA.
Study intervention
The intervention was done randomly assigned 
to receive an injection ampouls containing PROG 
1 mg/kg BW single dose. Randomization was performed 
with the use of a combination of minimization and 
biased-coin algorithms to avoid imbalances in sex, age, 
or enrollment site. Teams study followed the patients 
closely. Data on serious adverse events were collected 
throughout the duration of the study (3 months), and 
data on all adverse events were collected during the 
1st week. Data on clinical transgressions were collected 
and reported daily during hospitalization.
Study outcomes
The primary outcome was functional recovery 
as determined with the use of the GOS at 3 months 
after randomization. A GOS score of one indicates 
death, two indicates a vegetative state, three indicates 
severe disability, four indicates moderate disability, 
and five indicates good recovery. The index GCS 
score, the highest reliable GCS score documented 
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before randomization. Moreover, the index CT scan is 
classified by Marshall CT classification.
Statistical analysis
Secondary data are shown as a frequency 
distribution and standard deviation using the descriptive 
statistical analysis. Normality test using Kolmogorov–
Smirnov needed to determine the form of data distribution, 
as this can decide the statistic parametric used (parametric/
non-parametric). t-test comparative test used to compare 
the value of S-100B, IL-6, and AQP4. Pearson correlative 
test is used to find any correlation between S-100B, 
IL-6, and AQP4 with GOS 3 months. Moreover, ANOVA 
repeated measured test to find any correlation of changes 
of value between the two groups based on S-100B, IL-6, 
and AQP4 value. The results of the analysis are said to be 
significant if p < 0.05 with a 95% confidence level. Data 
were analyzed using SPSS version 22.
Results
Patients characteristic
Patients were recruited from November 2011 
to November 2012, with the final 3-month visit occurring 
by the end of November 2012. A total of 40 patients 
underwent randomization, with intramuscular 
administration of PROG initiated in 17 patients and 
control administered in 23 patients. One patient was 
excluded because they did not receive the complete 
evaluation for GOS 3 months. There were no meaningful 
protocol violations. This study is done on 39 man with 
age from 15 to 60 years, severe TBI with GCS of 4–8, 
blunt trauma with time injury of <24 h, and from the CT 
scan did not show the Marshal type IV criteria (Table 1).
This research is done on two groups. Control 
group is the majority with 23 subjects (59%) and treated 
group with 16 subjects (41%). The age of control group 
is 18 years old as the majority range (21.7%) incidence 
of the accident, meanwhile on treatment group is 
19 years (17.4%), Table 1.
GCS and CT scan characteristic
The mean value of GCS day 1 on all subjects 
is 5.88 (median 6) and 6.25 on day IV (median 6). The 
GCS mean value trends to recovery condition in both 
groups (p = 0.001).
Diffuse injury type II is the most radiographic 
finding in this study (>50%). There was no finding of 
diffuse injury type IV in both groups that means MLS 
>0.5 cm the patient will performed surgery operative.
Biomarker characteristic
There was no significant comparison (p > 0.05) 
change on serum level of S-100β, AQP4, and IL-6, 
between progesterone group and control group 
(Table 2).
In assess subgroup analysis biomarker statue 
change within 24 h and 96 h, we found significant 
value in both control (all biomarker had value p < 0.05). 
The mean value of each biomarker will give the trend 
increasing or decreasing.
In study of progesterone group, we found that 
the mean value S-100β 24 h is 40.57 and 96 h is 44.75. 
(p = 0.02). It means that S-100β expression tends to 
increasing. The others biomarker (AQP4 and IL-6) in 
PROG group showed tend to increasing too (p < 0.05).
There was a difference in control group. 
S-100β and IL-6 serum level showed decreasing but 
AQP4 showed increasing (p < 0.05)
In this subgroup analysis study, we assess 
correlation value of serum biomarker and the GCS 24 h 
and 96 h. We found significant value in progesterone 
group 96 h for serum S-100β (p = 0.025), and value in 
control group 24 h (p = 0.000) and 96 h (p = 0.000) for 
serum S-100β too.
Can serum biomarker for the first 24 h can 
predict severity of Marshall classification of CT scan. 
We found only IL-6 serum level had significant value 
in assess the correlation biomarker and CT scan 
(p = 0.029).
Intervention and outcomes
Adverse events
There was no adverse event found in this 
research. There was no blood or lymphatic system 
disorder, cardiac disorder, endocrine disorder, 
Table 1: Baseline of characteristic (subgroup analysis)
Characteristic Progesterone (n=16) Control (n=23)
Age–year x̄=24.69 x̄=23.26
Median 19 19.5
Age group – no.%
<20 years old 8 (50) 12 (52.17)
20–40 years old 7 (43.75) 10 (43.48)
>40 years old 1 (6.25) 1(4.35)
Total 16 (41) 23 (59)
Male sex – no. % 16 (100) 23 (100)
Cause of injury – no.%
Motorcycle accident 33 (84.6)
Fall 6 (15.4)
Glasgow Coma Scale score – no.% 24 h 96 h 24 h 96 h
4 1 (6.3) 3 (18.8) 6 (26.1) 5 (21.7)
5 5 (31.3) 4 (25.0) 7 (30.4) 4 (17.4)
6 6 (37.5) 2 (12.5) 4 (17.4) 4 (17.4)
7 3 (18.8) 1 (6.3) 2 (8.7)
8 1 (6.3) 5 (31.3) 4 (17.4) 3 (13.0)
9 1 (6.3) 4 (17.4)
10 2 (8.7)
12 1 (4.3)
x̄=5.88 x̄=6.25
Marshall classification – no.%
Type I 0 4 (17.4)
Type II 10 (62.5) 12 (52.2)
Type III 6 (37.5) 7 (30.4)
Type IV 0 0
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gastrointestinal disorder, infection, and nervous system 
disorder as previous warning report of progesterone 
side effect [32], [33].
Efficacy analysis
There was disappointed result about 
efficacy analysis of progesterone used in this study. 
Progesterone showed no significant value from control 
group with test comparison statistical study (p = 0.864) 
within GOS 3 months.
Next, we assess to approach by sliding 
dichotomy GOS as now technique (Table 3). The result 
showed that no difference outcome from progesterone 
group and control group (p > 0.05).
In addition, we found in last subgroup analysis 
to found the serum biomarker as surrogate marker. 
Serum level of S-100β showed promising as biomarker 
that predicts outcome of TBI. In this study, the day 
4 (96 h) in both groups showed of serum level S-100β 
had significant value for predict the outcome GOS 
3 months (p = 0.000).
Discussion
Demographic characteristic
The youngest age of this subject is 16 and 
the oldest is 47 and is corresponding to the inclusion 
criteria. The productive age is reportedly the prone 
group of occurrence of brain injury. This is because of 
mobilization of productive group and the use of motor 
vehicle increased rapidly in Indonesia as a developing 
country [2]. All the subject is man. Indirectly, the existence 
of men as the subject hindering the bias of information 
that woman with brain injury have better outcome of 
brain injury [23]. Women have gestational sex hormone 
thought that theoretically may be affect the outcome 
of brain injury. Menopause female patient reportedly 
have improved outcome in postmenopausal but not 
premenopausal female of outcome of brain injury [34].
GCS
The mean value of GCS day 1 on all subject 
is 5.72 (median 6) and 6.56 on day 4 (median 6). GCS 
Table 2: Result of Biomarker change analysis
Biomarker Progesterone (n=16) Control (n=16) Sig. (95% CI)
x̄ Min Max SD x̄ Min Max SD Between group comparation
24 h
S-100β 40.57 19 67 10.377 46.11 11 147 23.893 p=0.136
AQP4 0.75 0 0 0.872 0.62 0 0 0.843 p=0.847
IL-6 0.12 0 0 0.111 0.2 0 1 0.259 p=0.123
96 h
S-100β 44.75 36 77 10.242 42.51 12 67 10.660 p=0.477
AQP4 0.85 3 3 0.906 0.74 4 4 1.021 p=0.813
IL-6 0.14 0 0 0.136 0.17 0 0 0.220 p=0.482
Subgroup analysis
Biomarker on progesterone group within 24 h and 96 h (Pearson correlation)
S-100β x̄ increasing p=0.021 ↑
AQP4 x̄ increasing p=0.000 ↑
IL-6 x̄ increasing p=0.000 ↑
Biomarker on control group within 24 h and 96 h (Pearson correlation)
S-100β x̄ decreasing p=0.01↓
AQP4 x̄ increasing p=0.00 ↑
IL-6 x̄ decreasing p=0.00 ↓
Biomarker with GCS (Pearson correlation)
GCS 24 h GCS 96 h
Progesterone group 24 h/96 h x̄=5.88 x̄=6.25 p=0.000 ↑
S-100β x̄ increasing 0.033/0.204 0.118/0.025
AQP4 x̄ increasing 0.869/0.061 0.874/0.550
IL-6 x̄ increasing 0.766/0.459 0.742/0.621
Control group 24 h/96 h x̄=5.61 x̄=6.78 p=0.000 ↑
S-100β x̄ decreasing 0.073/0.000 0.086/0.000
AQP4 x̄ increasing 0.905/0.853 0.257/0.301
IL-6 x̄ decreasing 0.157/0.266 0.215/0.155
Biomarker 24 h can predict severity of Marshall classification of CT scan
Progesterone group (24 h) Marshall classification of CT scan (Sig. CI 95%)
S-100β x̄ increasing p=0.945
AQP4 x̄ increasing p=0.426
IL-6 x̄ increasing p=0.698
Control group (24 h)
S-100β x̄ decreasing p=0.549
AQP4 x̄ increasing p=0.274
IL-6 x̄ decreasing p=0.029
AQP4: Aquaporin-4, CT: Computerized tomography, IL-6: Interleukin 6, GCS: Glasgow Coma Scale.
Table 3: Sliding GOS dichotomy approach
GOS 3 months Worst prognosis Intermediate prognosis Best prognosis
Progesterone Control Progesterone Control Progesterone Control
Death Unfavorable
8 (50%)
Unfavorable
12 (52.17%)
Unfavorable
13 (81.25%)
Unfavorable
19 (82.61%)
Unfavorable
16 (100%)
Unfavorable
22 (95.65%)Vegetative state
Severe disability
Favorable
8 (50%)
Favorable
11 (47.83%)
Moderate disability Favorable
3 (18.75%)
Favorable
4 (17.39%)Good recovery Favorable
0
Favorable
1 (4.35%)
Sig. (95%CI) p=0.285 p=0.819 p=0.827
GOS: Glasgow outcome scale.
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of all subjects is GCS 5 on day 1 and GCS 8 on day 
4. This research showed recovery GCS in all subject 
according to assess mean difference, however the 
overall outcome showed no significance. GCS is still 
used as an indicator to predict the severity of and the 
prognostic of severe TBI [35].
CT scan characteristic
Brain CT scan is still considered as gold 
standard diagnosis of severe TBI. Marshall created 
criteria of CT scan as an imaging of neural injury on 
severe TBI. Cerebral edema can be shown on brain CT 
scan with type I-IV. In type IV with presented midline 
shift >5 mm always facing the surgical indication with 
excluding cases in this research [36].
Cerebral edema is the main topic of this study, 
S-100β, IL-6, and AQP4 reportedly used as a marker 
of BBB rupture [5], [8], [10], [15], [17] BBB rupture 
on cerebral edema causing the release biochemical 
marker to the systemic. BBB rupture and neural injury 
on TBI cannot be distinguished from the cerebral 
edema [14]. However, in this research showed only the 
increasing of serum IL-6 that explained in severe TBI 
often increasing intracranial pressure (ICP) that more 
sensitive by IL-6 change [8]. The first limitation of this 
research is no examination or data collected about the 
ICP.
S100β, AQP4, and IL-6 on treatment group
The result of this study showed increasing 
value of blood serum of S-100β and IL-6 but increasing 
serum of AQP4 after the administration of PROG 1 mg/
kg BW intramuscular single doses. The change serum 
level probably the dosage was suboptimal.
The mean value of three biomarker in PROG 
group showed tends to increasing on S-100β, IL-6 
and AQP4. The same dynamic change only showed 
AQP4 increasing in both groups. This mechanism may 
be explained PROG as inhibitors of AQP-4 stimulate 
S-100β secretion in acute severe TBI [16].
Biomarker and GOS in severe TBI
This study showed significance correlation of 
serum level S-100β day 4 (96 h) in both groups that 
predict the outcome GOS 3 months. In acute dynamic 
condition (day 1 until day 3) of severe, TBI may be the 
process have high complexity. There was a another 
extracranial injury that involves bias or change in 
S-100β serum level [37], [38], [39].
Based on Korfias et al., the degree of severity 
of the patients shows different expression of S-100β [40]. 
After 20 years, S-100β suggests as a prognostic indicator 
on research of brain injury, brain ischemic, and drug 
study that have a potential value of increasing person life 
expectancy in brain trauma patient [6], [7], [38], [40]
Clinical outcomes
The primary endpoint, the GOS score at 3 months, 
did not differ significantly between the PROG group and 
the control group (Tables 3 and 4). The proportional-odds 
model revealed no effect of PROG treatment in either 
unadjusted or adjusted analyses by sliding dichotomy 
approach. The proportion of patients with an overall 
favorable outcome (good recovery or moderate disability) 
on the GOS was 18.75% in the PROG group and 17.9% 
in the control group. The proportion of patients who were 
in a vegetative state or who died was also similar in the 
two groups: 81.25% in the PROG group and 82.61% in 
the control group. This research results do not support the 
hypothesized superiority of PROG treatment over treated 
group in patients with severe TBI, as assessed by means 
of the GOS or approach to sliding GOS dichotomy [32].
The other investigation of eight randomized 
controlled trials meta-analysis in PROG administration 
improves the clinical outcomes of severe TBI patients 
within 3 months post-injury but may not have significant 
long-term benefits at 6 months post-injury [33].
Heterogeneity: Single bullet versus 
multitarget therapy
The long history of failed TBI trials, including the 
current trial, is probably due to several factors, including 
Table 4: Result of efficacy analysis
Outcome (GOS 3 mt) Progesterone (n=16) Control (n=23) Sig. (95% CI) comparison
Primary efficacy analysis – no.% x̄ = 2.38. SD=1.147 x̄ = 2.57. SD=1.037 p=0.864
Dead 5 (31.3) 3 (13.0)
Vegetative state 3 (18.8) 9 (39.1)
Severe Disability 5 (31.3) 7 (30.4)
Moderate disability 3 (18.8) 3 (13.0)
Good recovery 0 1 (4.3)
Subgroup analysis 
Biomarker – GOS prediction
Progesterone Group 24 h Sig. (CI=95%) 96 h Sig. (CI=95%)
S-100β x̄ decreasing p=0.206 p=0.000
AQP4 x̄ increasing p=0.217 p=0.172
IL-6 x̄ decreasing p=0.225 p=0.290
Control group
S-100β x̄ increasing p=0.021 p=0.000
AQP4 x̄ increasing p=0.928 p=0.211
IL-6 x̄ increasing p=0.212 p=0.114
AQP4: Aquaporin-4, IL-6: Interleukin 6, GOS: Glasgow Outcome Scale.
 Mahyudaniletal.TheEffectofProgesteroneTherapyinSevereTraumaticBrainInjury
Open Access Maced J Med Sci. 2020 May 01; 8(B):236-244. 241
the complexity and variability of the injury and the fact 
that multiple direct and indirect injury mechanisms are 
at work simultaneously [32], [41], [42].
TBI is a complex disease and has a pathology 
process, heterogeneous disorder, in which the primary 
injury initiates a variety of secondary injury cascades. 
These cascades involve various processes that may 
not be responsive to monotherapy (single bullet), as 
has been shown by the failure of previously studied 
monotherapies that have targeted single receptors or 
specific mechanisms, despite considerable supportive 
experimental data. Systemic and extraneuronal effects 
of trauma also require consideration with respect to their 
effect on mortality among patients with TBI [32], [42].
These complex injury mechanisms suggest that 
a successful therapeutic agent should influence several 
mechanisms rather than a single cascade. On the basis 
of the experimental data, PROG would appear to be an 
appropriate candidate for this multipotential role, having 
been shown to prevent inflammation by inhibiting the 
production of inflammatory cytokines (e.g., tumor 
necrosis factor-α), as well as by reducing levels of 
inflammation-related factors such as complement 
factor C3 fragments and inhibiting the activation of 
microglial cells. In addition PROG has been shown to 
prevent excitotoxicity and limits apoptosis by preventing 
biochemical insults, such as calcium (Ca2+) flux and 
nitric oxide production, and by decreasing levels of 
caspase 3. Finally, PROG has also been shown to limit 
vasogenic edema through reconstitution of the BBB and 
modulation of the AQP4 water transporter [32], [41].
Dosage adjusted and solubility
This study used the administration of PROG 
1 mg/kg BW intramuscular single doses. In this 
research, the choosing of maintenance dose as Xiao 
publication in China had not been done because there 
was no absolute recommendation on dosage and 
delivery technique on research report before.
The analysis stratified by administration route 
showed that beneficial effects were only observed in 
patients who received PROG intramuscularly [33]. 
Preliminary clinical data obtained with the use of various 
PROG formulations and routes of delivery, combined 
with experimental data showing adequate brain 
penetration, provided initial support for a neuroprotective 
role of PROG in TBI. The initial PROTECT trial recruited 
100 patients from a single site who had a GCS score of 
4–12. Treatment was initiated within 11 h after injury, 
with a 72-h treatment duration, and was associated 
with a reduction in the rate of death from any cause, 
as compared with placebo. A similar single-site trial in 
China recruited 159 patients who had a GCS score of 
8 or lower. PROG treatment, which was initiated within 
8 h after injury by means of intramuscular injection, 
with a 120-h treatment duration, was associated with 
reduced mortality, as compared with placebo [32].
Drug dose and delivery route are important 
parameters that influence clinical efficacy. Of the included 
trials, PROG was administered intravenously in three 
studies and intramuscularly in four. One study gave a 
medroxyprogesterone tablet through nasogastric tube. Our 
analysis showed that PROG only conferred neuroprotection 
in patients who were given PROG intramuscularly. 
The discrepancy in the efficacies of intravenous and 
intramuscular administration is unclear [33].
When we evaluated the pharmacological 
profile of the presentations tested for clinical efficacy, 
most of the available drugs are poorly acidic or poorly 
basic and have low aqueous solubility. These poorly 
soluble drugs in water evolve with low absorption 
rates, which can result in low tissue bioavailability, 
being critical for their rapid and effective action, as 
in brain injury. The solubility dilemma is a major 
challenge for its formulation. Solubility is an important 
parameter in obtaining drugs with the ability to 
achieve the desired concentration in the brain and 
other tissues [43].
Due to progesterone’s plasma half-life of only 
25 min, it is necessary to take it to the brain rapidly, 
which in practical conditions would require immediate 
continuous IV post-trauma treatment. It can be stated 
that the dripping or use of multiple injections in a lipid-
based vehicle delays the release into the systemic 
circulation and results in a consequent reduction of the 
expected protective properties of PROG in the acute 
phase of TBI. This feature is important and makes it 
difficult to “replicate” the compelling results obtained in 
pre-clinical trials in guinea pigs [43].
Insensitivity of the outcome measures
However, recovery from severe TBI is a 
slow gradual process, mortality and GOS score are 
not sufficiently sensitive to quantitatively measure 
functional deficits and gradual recovery over time [33]. 
There may also be insensitivity of the available outcome 
measures [32], [44], [42].
The lack of mechanistic early endpoints and 
the absence of reliable biomarkers to guide clinical 
development and inform clinical-trial design may be 
considered to be major obstacles to the development 
of neuroprotective agents for TBI. In addition, current 
approaches to the characterization of TBI are mainly 
unidimensional (based on GCS scores or Marshall 
classification) and do not permit appropriately targeted 
therapy. Multidimensional approaches are needed for 
better characterization of TBI to facilitate individualized 
treatment [32], [42], [44],
Future animal study
PROG has been shown to have broad 
neuroprotective properties in multiple animal species 
B - Clinical Sciences Surgery
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and in a variety of models of neurologic injury. 
Multifactorial effects of PROG include inhibition of 
inflammatory cytokines, reduced levels of inflammation-
related factors, prevention of excitotoxicity, reduction of 
apoptosis, and control of vasogenic edema.
The PROG receptor plays a key role in these 
neuroprotective effects. A total of 20 research groups 
working with four species and 22 different models have 
found neuroprotective effects of PROG in more than 
180 experimental pharmacologic studies. In addition, 
two phase II randomized, controlled clinical trials with 
PROG showed a clinical benefit. On the basis of these 
collective data, two phase III trials were initiated at 
around the same time: The study of a neuroprotective 
agent, PROG, in severe TBI (SYNAPSE), and the PROG 
for the treatment of TBI (PROTECT III) trial. SYNAPSE, 
a trial sponsored by BHR Pharma, was designed 
to investigate the clinical effectiveness of PROG, 
provided in a 6% soybean oil emulsion as a ready-to-
use formulation, under well-controlled conditions. The 
PROTECT III trial, funded by the National Institutes of 
Health, was conducted in parallel, but the study was 
halted on the basis of a futility analysis performed after 
882 patients had undergone randomization.
In conclusion, PROG as administered in this trial 
had no clinical benefit in the treatment of severe TBI. The 
negative result of this study should stimulate a rethinking 
of procedures for drug development and testing in TBI.
Limitations in the ability to translate 
experimental data to the context of TBI in humans 
may also have contributed to the trial failures. A more 
systematic approach appears to be necessary to 
advance therapeutics in TBI.
Endogenous Progesterone
Stein DG, 2016 said that the clinical phase III 
of PROG has no effect of improvement in TBI patients 
as in control population, this can be caused from: 
Heterogenecity, the different definition of brain trauma, 
the needs of thorough study on animal study, use of 
other sensitive biomarker from serum and inflammation 
cascade, the report of data and the chance of no 
sensitivity of outcome scale result [42].
As an addendum, the cause of failure from this 
study can be caused no examination of endogenous 
level of progesterone. Because of progesterone is in 
cell nucleus, thus needed more thorough study of 
mechanism of PROG from the pharmacokinetic to 
pharmacodynamic so that can be shown what disrupt the 
pathway of pharmacokinetic and pharmacodynamics of 
PROG itself [45].
PROG concentration changes according to 
age. The highest concentration of PROG is in neonates, 
and in 1–12 months children, the value is decreasing 
1/3 times from the neonate. Genazzini et al. in 1998 
found that PROG value decreased from 19 until over 
60 years. Davis et al. study reported that the identical 
pattern of improved outcomes in postmenopausal 
but not premenopausal females versus age-matched 
males was observed. However, Davis et al. reported 
that endogenous female sex hormone production is not 
neuroprotective [34].
In humans, PROG levels in both the plasma 
and CSF rapidly and transiently increase after severe 
TBI possibly as part of the endogenous protective 
response. The addition of exogenous PROG may 
augment the physiological neuroprotective [43]. Further 
research is yet to be done to assess the pharmacological 
effect of PROG.
Conclusion
S-100β serum levels can be used as surrogate 
marker for TBI prognosis in clinical research especially 
new potential drug. Serum S-100β is significant enough 
to predict the outcome of severe TBI.
Progesterone effect on severe TBI patient with 
biomarker testing still had unclearly concept theory in 
repairing neuronal injury and/or BBB disruption. The 
other consideration is about concept theory of temporal 
trajectory S100β, AQP4, and IL-6 in serum level after TBI.
For the future study, suggestion is necessary to 
investigation endogenous PROG naturally especially in 
TBI. Introducing serum biomarkers such as S-100β in future 
pharmaceutical trials may be possible to better monitoring 
the effect of specific pharmacological treatments.
Ethical Clearance
Research approval was obtained from the 
Ethics Committee of the Medical Faculty, University of 
Airlangga – Central Hospital Dr. Soetomo, East Java, 
Indonesia. Every research subject has the right to know 
the results of the examination conducted on him.
References
1. Engel DC. Secondary Damage After Traumatic Brain Injury: 
Epidemiology, Pathophysiology and Therapy. Rotterdam: 
Erasmus Universiteit; 2008.
2. RISKESDAS. Indonesia Ministry of Health, Health Research 
 Mahyudaniletal.TheEffectofProgesteroneTherapyinSevereTraumaticBrainInjury
Open Access Maced J Med Sci. 2020 May 01; 8(B):236-244. 243
and Development. Jakarta, Indonesia: Indonesia Ministry of 
Health; 2018.
3. Reilly PR, Selladurai BE. Pathophysiology of acute non 
missile head injury. In: Initial Management of Head Injury, a 
Comprehensive Guide. Australia: McGraw-Hill Australia Pty 
Limited.; 2007. p. 10-32.
4. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S-100B 
serum levels and long-term improvement of negative symptoms 
in patients with schizophrenia. Neuropsychopharmacology. 
2004;29(5):1004-11. https://doi.org/10.1038/sj.npp.1300403
 PMid:14997170
5. Kleindienst A, Ross Bullock M. A critical analysis of the role 
of the neurotrophic protein S-100B in acute brain injury. 
J Neurotrauma. 2006;23(8):1185-200. https://doi.org/10.1089/
neu.2006.23.1185
 PMid:16928177
6. Tala MI, Darmadipura S. Hubungan Perubahan Kadar Protein 
S-100β Dalam Cairan Serebrospinalis Dengan Tingkat 
Kesadaran Pasien Cedera Otak Berat. Karya Akhir S2 Skripsi. 
Surabaya, Indonesia: Airlangga University-School of Medicine; 
2008.
7. Ndraha E, Bajamal AH. Hubungan Antara Perubahan Kadar 
S-100β Pada Pasien Cedera Kepala Berat Pada Fase Akut 
Dengan Outcome. Karya Akhir S2 Skripsi. Surabaya, Indonesia: 
Airlangga University-School of Medicine; 2010.
8. Hergenroeder GW, Moore AN, McCoy JP, Samsel L, Ward NH, 
Clifton GL, et al. Serum Il-6: a candidate biomarker for 
intracranial presure elevation following isolated traumatic 
brain injury. J Neuroinflammation. 2010;7:19. https://doi.
org/10.1186/1742-2094-7-19
 PMid:20222971
9. Verkman AS. Aquaporins: Translating bench research to human 
disease. J Exp Biol. 2008;212(Pt 11):1707-15. https://doi.
org/10.1242/jeb.024125
 PMid:19448080
10. Oliviera CO, Ikuta N, Regner A. Outcome biomarker 
following severe traumatic injury. Rev Bras Ter Intensiva. 
2008;20(4):411-21.
 PMid:25307248
11. Raheja A, Sinha S, Samson N, Bhoi S, Subramanian, A, 
Sharma P, et al. Serum biomarkers as predictors of long-term 
outcome in severe traumatic brain injury: Analysis from a 
randomized placebo-controlled Phase II clinical trial. J Neurosurg. 
2016;125(3):631-41. https://doi.org/10.3171/2015.6.jns15674
 PMid:26722854
12. Van Landingham JW, Cutler SM, Cekik M, Wright D, Stein DG. 
Serum biomarker profiling for progesterone treatment of 
traumatic brain injury: A comparative study human and rat. 
FASEB J. 2006;20:1314-25.
13. Thelin EP, Zeiler FA, Ercole A, Mondello S, Büki A, Bellander B, 
et al. Serial sampling of serum protein biomarkers for 
monitoring human traumatic brain injury dynamics: A systematic 
review. Front Neurol. 2017;8:300. https://doi.org/10.3389/
fneur.2017.00300
 PMid:28717351
14. Thelin EP, Nimer FA, Frostell A, Zetterberg H, Blennow K, 
Nystrom H, et al. A serum protein biomarker panel improves 
outcome prediction in human traumatic brain injury. 
J Neurotrauma. 2019;36(20):2850-62. https://doi.org/10.1089/
neu.2019.6375
 PMid:31072225
15. Miao X, Wei S, Qiu-Ping X. Aquaporin-4 and traumatic brain 
edema. Chin J Traumatol. 2010;13(2):103-10.
 PMid:20356447
16. Zanotto C, Abib RT, Batassini C, Tortorelli LS, Biasibetti R, 
Nardin LR, et al. Non-specific inhibitors of aquaporin-4 
stimulate S-100B secretion in acute hippocampal slices of 
rats. Brain Res. 2013;1491:14-22. https://doi.org/10.1016/j.
brainres.2012.10.065
 PMid:23142267
17. Thelin EP, Nelson DW, Bellander BM. A review of the clinical 
utility of serum S-100B protein levels in the assessment of 
traumatic brain injury. Acta Neurochir. 2017;159:209-25. https:// 
doi.org/10.1007/s00701-016-3046-3
 PMid:27957604
18. Cutler SM. The Effect of Progesterone Withdrawal on Behavioral 
and Molecular Indices after Traumatic Brain Injury, PhD Thesis. 
Georgia: Georgia Institute of Technology; 2005.
19. Cutler SM, Milos C, Miller DM, Wali B, Vanlandingham JW, 
Stein DG. Progesterone improves acute recovery after traumatic 
brain injury in the aged rat. J Neurotrauma. 2007;24:1475-86. 
https://doi.org/10.1089/neu.2007.0294
 PMid:17892409
20. Schumacher M, Guennoun R, Ghoumari A, Massaad C, 
Robert  F. Novel perspectives for progesterone in hormone 
replacement therapy, with special reference to the nervous 
system. Endocr Rev. 2007;28(4):387-439. https://doi.
org/10.1210/er.2006-0050
 PMid:17431228
21. Stein DG. Progesterone exerts neuroprotective effects after 
brain injury. Brain Res Rev. 2008;57:386-97. https://doi.
org/10.1016/j.brainresrev.2007.06.012
 PMid:17826842
22. Stein DG, Wright DW, Kellermann AL. Does progesterone have 
neuroprotective properties? Ann Emerg Med. 2008;51(2):164-
72. https://doi.org/10.1016/j.annemergmed.2007.05.001
 PMid:17588708
23. Farace E, Alves WM. Do women fare worse? A metaanalysis 
of gender differences in outcome after traumatic brain injury. 
J Neurosurg. 2000;93(4):539-45. https://doi.org/10.3171/
jns.2000.93.4.0539
 PMid:11014529
24. Wright DW, Bauer ME, Hoffman SW, Stein DG. 
Serum progesterone levels correlate with decreased 
cerebral edema after traumatic brain injury in male 
rats. J Neurotrauma. 2001;18(9):901-9. https://doi.
org/10.1089/089771501750451820
 PMid:11565602
25. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The 
neurosteroids progesterone and allopregnanolone reduce 
cell death, gliosis, and functional deficits after traumatic brain 
injury in rats. J Neurotrauma. 2005;22(1):106-18. https://doi.
org/10.1089/neu.2005.22.106
 PMid:15665606
26. Yao XL, Liu J, Lee E, Ling GS, Mccabe JT. Progesterone differentially 
regulates pro and anti-apoptotic gene expression in cerebral 
cortex following traumatic brain injury in rats. J Neurotrauma. 
2005;22(6):656-68. https://doi.org/10.1089/neu.2005.22.656
 PMid:15941375
27. Chen G, Shi J, Ding Y, Yin H, Hang C. Progesterone prevents 
traumatic brain injury-induced intestinal nuclear factor kappa 
b activation and proinflammatory cytokines expression in 
male rats. Mediators Inflamm. 2007;2007:93431. https://doi.
org/10.1155/2007/93431
 PMid:18274644
28. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M. 
proTECT: A randomized clinical trial of Progesterone for acute 
traumatic brain injury. Ann Emerg Med. 2006;20(10):1-13.
29. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for 
the treatment of experimental brain injury; a systematic review. 
B - Clinical Sciences Surgery
244 https://www.id-press.eu/mjms/index
Brain. 2008;31:318-28. https://doi.org/10.1093/brain/awm183
 PMid:17715141
30. Gibson CL, Coomber B, Rathbone J. Is Progesterone a 
candidate neuroprotective factor for treatment following 
ischemic stroke? Neuroscientist. 2009;15(4):324-32. https://doi.
org/10.1177/1073858409333069
 PMid:19359672
31. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes 
from the administration of progesterone for patients with acute 
severe traumatic brain injury: A randomized controlled trial. Crit 
Care. 2008;12(2):R61. https://doi.org/10.1186/cc6887
 PMid:18447940
32. Skolnick BE, Maas AI, Narayan RK, van der Hoop RG, 
MacAllister T, Ward JD, et al. A clinical trial of progesterone for 
severe traumatic brain injury. N Engl J Med. 2014;371(26):2467-
76. https://doi.org/10.1056/nejmoa1411090
 PMid:25493978
33. Pan ZY, Zhao YH, Huang WH, Xiao ZZ, Li ZQ. Effect of 
progesterone administration on the prognosis of patients with 
severe traumatic brain injury: A meta-analysis of randomized 
clinical trials. Drug Des Dev Ther. 2019;13:265-73. https://doi.
org/10.2147/dddt.s192633
 PMid:30666088
34. Davis DP, Douglas JD, Smith DW, Sisegary M, Troy LV, 
Kennedy A, et al. Post-menopausal females versus age-
matched males. J Neurotrauma. 2006;23(2):140-8.
 PMid:16503798
35. Chesnut RM, Ghajar J, Maas AI, Marion DW, Servadei F. 
Early indicators of prognosis in severe traumatic injury. In: 
Part II Management and Prognosis of Severe Traumatic 
Injury. A Joint project of Brain Trauma Foundation. New York: 
American Association of Neurological Surgeon, Joint section 
of Neurotrauma and Critical Care, Brain Trauma Foundation; 
2003. https://doi.org/10.1089/neu.2000.17.555
36. Cooper PR. Post traumatic intracranial mass lesion. In: Cooper 
PR, editor. Head Injury. Baltimore: Williams and Wilkins; 1993. 
p. 275-330.
37. Benjamin A, Matthew L, Hitomi, E, Peng W, Liao Y, Lou N, et al. 
Biomarkers of traumatic injury are transported from brain to 
blood via the glymphatic system. J Neurosci. 2015;35(2):518-
26. https://doi.org/10.1523/jneurosci.3742-14.2015
 PMid:25589747
38. Thelin EP, Nelson DW, Bellander BM. A review of the clinical 
utility of serum S100B protein levels in the assessment of 
traumatic brain injury. Acta Neurochir. 2017;159(2):209-25. 
https://doi.org/10.1007/s00701-016-3046-3
 PMid:27957604
39. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, 
et al. Extracranial Sources of S100B Do Not Affect Serum 
Levels. PLoS One. 2010;5(9):e12691. https://doi.org/10.1371/
journal.pone.0012691
 PMid:20844757
40. Korfias S, Stranjalis G, Papadimitriou A, Psachoulia C, 
Daskalakis G, Antsaklis A, et al. Serum S-100B protein as 
a biochemical marker of brain injury: A review of current 
concept. Curr Med Chem. 2006;13(30):3719-31. https://doi.
org/10.2174/092986706779026129
 PMid:17168733
41. Wei J, Xiao GM. The neuroprotective effects of progesterone on 
traumatic brain injury: current status and future prospects. Acta 
Pharmacol Sin. 2013;34(12):1485-90. https://doi.org/10.1038/
aps.2013.160
 PMid:24241345
42. Stein DG. Embracing failure: What the Phase III progesterone 
studies can teach about TBI clinical trials. Brain Inj. 
2015;29(11):1259-72. https://doi.org/10.3109/02699052.2015.1
065344
 PMid:26274493
43. Eduardo OD, Luciano MP. Medical theory: Why does 
progesterone not work after a traumatic brain injury in humans? 
Am J Biomed Sci Res. 2019;5(4):929.
44. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, 
Frankel M, et al. Very early administration of progesterone for 
acute traumatic brain injury. N Engl J Med. 2014;371(26):2457-
66. https://doi.org/10.1056/nejmoa1404304
 PMid:25493974
45. Zhu X, Frechou M, Liere P, Zhang S, Pianos A, Fernandez N, et al. 
A role of endogenous progesterone in stroke cerebroprotection 
revealed by the neural-specific deletion of its intracellular 
receptors. J Neurosci. 2017;37(45):10998-1020. https://doi.
org/10.1523/jneurosci.3874-16.2017
 PMid:28986464
